Large Molecule Drug Substance CDMO Market Worth $22.1 Billion By 2030

Large Molecule Drug Substance CDMO Market Growth & Trends

The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.3% from 2023 to 2030. Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.

Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities. Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.

Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

 Request a free sample copy or view report summary: Large Molecule Drug Substance CDMO Market Report

Large Molecule Drug Substance CDMO Market Report Highlights

• The contract manufacturing service segment dominated the market with a revenue share of over 65.0% in 2022

• Based on source, the mammalian segment accounted for the largest share of over 55.0% in 2022. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody–drug conjugates are evolved

• Based on end-user, the biotech companies segment accounted for the largest share of over 40.0% in 2022. Rising R&D investment by the firms for large molecules drives the market

• Asia Pacific is projected to register the fastest CAGR of 10.4% during the forecast period. The large patient base, lower overall costs, skilled workforce, and changes in the regulatory scenario are the key factors driving the market

Large Molecule Drug Substance CDMO Market Segmentation

Grand View Research has segmented the global large molecule drug substance CDMO market on the basis of service, source, end-user, and region:

Large Molecule Drug Substance CDMO Service Outlook (Revenue, USD Million, 2018 - 2030)

• Contract Manufacturing

  • Clinical

  • Commercial

• Contract Development

  • Cell Line Development

  • Process Development

Large Molecule Drug Substance CDMO Source Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian

• Microbial

• Others

Large Molecule Drug Substance CDMO End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Biotech Companies

• CRO

• Others

Large Molecule Drug Substance CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Rest of Europe

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

  • Rest of Asia Pacific

• Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Rest of Middle East and Africa

List of Key Players of Large Molecule Drug Substance CDMO Market

• Eurofins Scientific 

• WuXi Biologics

• Samsung Biologics

• Catalent, Inc.

• Rentschler Biopharma SE

• AGC Biologics

• Recipharm AB

• Siegfried Holding AG

• Boehringer Ingelheim

• FUJIFILM Diosynth Biotechnologies